Health
Novo Nordisk to Invest $158 Million in Brazilian Insulin Plant
Novo Nordisk is investing $158 million to revamp a plant in Brazil responsible for a quarter of the Danish company’s global insulin production.
This article is for subscribers only.
Novo Nordisk A/S is investing 864 million Brazilian reais ($158 million) to revamp a plant in Brazil responsible for a quarter of the Danish company’s global insulin production.
Novo said it will modernize its Montes Claros plant, in the southeastern state of Minas Gerais, and install sustainability projects. The facility, opened in 2007, produces insulin for Brazil’s national health system as well as for export.